Abstract:Myocardial dysfunction is a serious consequence of sepsis and contributes to high mortality. Currently, the molecular mechanism of myocardial dysfunction induced by sepsis remains unclear. In the present study, we investigated the role of gasdermin D (GSDMD) in cardiac dysfunction in septic mice and the underlying mechanism. C57BL/6 wild-type (WT) mice and age-matched Gsdmd -knockout ( Gsdmd -/- ) mice were intraperitoneally injected with lipopolysaccharide (LPS) (10 mg/kg) to mimic sepsis. The results showed that GSDMD-NT, the functional fragment of GSDMD, was upregulated in the heart tissue of septic WT mice induced by LPS, which was accompanied by decreased cardiac function and myocardial injury, as shown by decreased ejection fraction (EF) and fractional shortening (FS) and increased cardiac troponin I (cTnI), creatine kinase isoenzymes MB (CK-MB), and lactate dehydrogenase (LDH). Gsdmd -/- mice exhibited protection against LPS-induced myocardial dysfunction and had a higher survival rate. Gsdmd deficiency attenuated LPS-induced myocardial injury and cell death. Gsdmd deficiency prevented LPS-induced the increase of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in serum, as well as IL-1β and TNF-α mRNA levels in myocardium. In addition, LPS-mediated inflammatory cell infiltration into the myocardium was ameliorated and activation of NF-κB signaling pathway and the NOD-like receptor protein 3 (NLPR3) inflammasome were suppressed in Gsdmd -/- mice. Further research showed that in the myocardium of LPS-induced septic mice, GSDMD-NT enrichment in mitochondria led to mitochondrial dysfunction and reactive oxygen species (ROS) overproduction, which further regulated the activation of the NLRP3 inflammasome. In summary, our data suggest that GSDMD plays a vital role in the pathophysiology of LPS-induced myocardial dysfunction and may be a crucial target for the prevention and treatment of sepsis-induced myocardial dysfunction.

Host Gasdermin D restrains systemic endotoxemia by capturing Proteobacteria in the colon of high-fat diet-feeding mice

Deficiency of the Novel High Mobility Group Protein HMGXB4 Protects Against Systemic Inflammation-Induced Endotoxemia in Mice.

Gasdermin D Deficiency Does Not Protect Mice from High-Fat Diet-Induced Glucose Intolerance and Adipose Tissue Inflammation

GSDMD protects intestinal epithelial cells against bacterial infections through its N-terminal activity impacting intestinal immune homeostasis

Compound Loss of GSDMD and GSDME Function is Necessary to Achieve Maximal Therapeutic Effect in Colitis

P059 GSDMB triggers intestinal inflammation via regulating BHLHA15-mediated hyperactive unfolded protein response

Epithelial Gasdermin D shapes the host-microbial interface by driving mucus layer formation

Gasdermin D promotes development of intestinal tumors through regulating IL-1β release and gut microbiota composition

To die or not to die: Gasdermins in intestinal health and disease

Dysregulation of CD177+ neutrophils on intraepithelial lymphocytes exacerbates gut inflammation via decreasing microbiota-derived DMF

Gasdermin D is the only Gasdermin that provides protection against acute Salmonella gut infection in mice

GSDMD Mediates LPS-Induced Septic Myocardial Dysfunction by Regulating ROS-dependent NLRP3 Inflammasome Activation

GYY4137 Ameliorates Intestinal Barrier Injury in a Mouse Model of Endotoxemia.

Epithelial-derived gasdermin D mediates nonlytic IL-1β release during experimental colitis

Gasdermin D Licenses MHCII Induction to Maintain Food Tolerance in Small Intestine.

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Lactobacillus pentosus S-PT84 Prevents Low-Grade Chronic Inflammation-Associated Metabolic Disorders in a Lipopolysaccharide and High-Fat Diet C57/BL6J Mouse Model

Gasdermin D-Mediated Pyroptosis Promotes the Development of Atherosclerosis

The Regulation and Modification of GSDMD Signaling in Diseases

Intestinal Gasdermins for regulation of inflammation and tumorigenesis